Johnson & Johnson Dossier

Johnson & Johnson reported third-quarter FY2025 sales of .99 billion and an adjusted earnings per share (EPS) of .80, driven by performance in its Innovative Medicine and MedTech segments. The global healthcare leader generated .56 billion from pharmaceutical products and .43 billion from medical technology operations during the period. Following these results, management raised its full-year 2025 reported sales guidance to a range of .5 billion to .9 billion.

Financial Highlights

* Third-Quarter 2025 Reported Sales: .99 billion

* Third-Quarter 2025 Adjusted EPS: .80

* Innovative Medicine Segment Revenue: .56 billion

* MedTech Segment Revenue: .43 billion

* Full-Year 2025 Revenue Guidance: .5 billion - .9 billion

* Full-Year 2025 Adjusted EPS Guidance: .80 - .90

* Market Capitalization: 0.15 billion

* Current Dividend Yield: 3.1%

Johnson & Johnson is executing a strategic transformation to sharpen its focus on high-margin therapeutic and medical technology markets. A central component of this strategy is the planned... Sign in / Sign up to learn more about Johnson & Johnson

Continue your research by chatting with our AI financial analyst about Johnson & Johnson. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given Johnson & Johnson's strategic pivot to focus on higher-growth areas, how does the planned spin-off of the Orthopedics business alter the financial profile and competitive positioning of the remaining MedTech segment?
• With Johnson & Johnson raising its full-year FY2025 guidance, what specific products and pipeline developments within the Innovative Medicine segment are critical to offsetting the revenue decline from Stelara's loss of exclusivity?
• How does the ongoing talc litigation and the proposed settlement figure impact Johnson & Johnson's risk profile, and what is the potential effect on its free cash flow and capital allocation strategy for FY2025?
• Considering the performance disparity in FY2025, with Innovative Medicine growing faster than MedTech, how should investors evaluate Johnson & Johnson's capital allocation between the two segments, particularly regarding R&D and potential acquisitions?
• Based on Johnson & Johnson's forward P/E of 16.8, what market expectations for growth and risk, including the Orthopedics spin-off and litigation resolution, are currently priced into the stock?